Cancer to be tackled next by SBM's tech?This last paragraph seemed odd / out of place. They talk about diabetes for the whole paragraph which makes sense given the release pertains to their diabetes drug and clinical trial. Then they tag on the last line about Cancer? Subtle hint of what direction they are taking next with Wanbang? Perhaps Wanbang is seeing the tech work so well they dusted off some of their other compounds that could benefit from the carb stablization SBM's tech provides? Hopefully SBM is able to use the clinical trial information and start advancing negotiations for ROW for their SGLT2. SBM will really start snowballing their revenues once all their compounds start paying upfronts / milestones / royalties. Or just get taken out (hence Poison Pill measure)
"Worldwide, an estimated 8.5% of the adult population (422 million people) have type 2 diabetes, and about a quarter of them (148 million; 10.9% of the population) live in China. A recent study in China analyzed data from more than 400,000 adults suffering from type 2 diabetes. It was revealed that men and women with type 2 diabetes had a 32% and 64% greater risk of developing cancer, respectively, compared with their peers in the general population. Cancer is a leading cause of death in China."